Send us a text

Welcome to  our second episode of the Summer 23 season.  Awhile back we introduced  the new series  under the  brand #OMBCLShorts.    As the title implies, these are shorter episodes. Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23.  In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
Listen in, enjoy, and let us know what you think by sending us a message on Twitter, Facebook, or Instagram! @ourmbclife

And don't forget to rate and review the podcast! Thanks so much for listening!